China Shineway Pharmaceutical Group Limited Announces Board Changes
independent director of Henan Lingrui Pharmaceutical Co. Ltd. from March 2016 to March 2019; an independent director of Inner Mongolia Furui Medical Technology Co. Ltd. from April 2016 to April 2019, and has served as the secretary general of the China Association of Traditional Chinese Medicine/National Technical Committee of Standardization of Traditional Chinese Medicine since August 2005; an independent director of Hainan Huluwa Pharmaceutical Group Co. Ltd. and an independent director of Sailing Pharmaceutical Technology Group Co. Ltd. since June 2021. The Board announced that with effect from 1 April 2023, Ms. Cheng Li (Ms. Cheng) will cease to serve as an independent non-executive Director in order to devote more time to pursue her personal interests. Ms. Cheng has confirmed that she has no disagreement with the Board and that she is not aware of any matters in relation to her cessation as an independent non-executive Director need to be brought to the attention of the shareholders of the Company. The Board announced that following the above changes, with effect from 1 April 2023: Ms. Wang has been appointed as the chairman of the Remuneration Committee of the Company and a member of the Audit Committee and the Corporate Social Responsibility and Sustainability Committee of the Company; and Ms. Cheng has ceased to act as the chairman of the Remuneration Committee of the Company and a member of the Audit Committee and the Corporate Social Responsibility and Sustainability Committee of the Company.